Popular Pre-Market Trades in US Stocks
Banco Santander SA-Spon fell 4.30% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 19, the Shenzhen Financial Regulatory Bureau disclosed that Shenzhen successfully introduced a new branch of Banco Santander SA-Spon, demonstrating the attractiveness of Shenzhen's financial market, but failed to boost the stock price.
</li>
<li>
On December 18, Banco Santander SA-Spon released a green bond report detailing the allocation and impact of green bonds, which did not have a positive effect on the stock price.
</li>
<li>
On December 17, Santander Chile announced the issuance of dollar bonds through its EMTN program, which did not alleviate market concerns about its financial condition. Global capital flows intensified market volatility.
</li>
</ol>
Top Gainers in Pre-Market Trading in US Stocks
Prophase Labs rose 88.20% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 19, Prophase Labs signed a non-binding letter of intent with Advanced Biological Laboratories to plan a reverse merger. According to the agreement, ABL will become the majority shareholder of the merged entity, with an expected enterprise value of approximately $30 million and a potential announcement of a special cash dividend of up to $10 million. This news drove Prophase Labs' stock price up 49.48% in pre-market trading. Source: Reuters
</li>
<li>
On December 19, Prophase Labs' CEO Ted Karkus stated that the proposed transaction structure aims to provide meaningful short-term value to existing shareholders while connecting ProPhase with ABL Group, a global leader in molecular analysis, clinical research, and medical innovation. This statement further enhanced market confidence in Prophase Labs. Source: Reuters
</li>
<li>
On December 19, Prophase Labs' trading volume significantly increased to 37 million shares, while the company's three-month average daily trading volume was about 2.84 million shares. This indicates high market attention to the company's recent developments. Source: Reuters Strong demand for molecular biology products and significant capital inflows.
</li>
</ol>
Aimee Medical rose 29.93% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 19, BioMarin announced the acquisition of Amicus Therapeutics for approximately $4.8 billion in cash, with an acquisition price of $14.50 per share, a 33.1% premium over Amicus's last closing price. This news drove Amicus' stock price up 30% in pre-market trading.
</li>
<li>
On December 18, executives of Amicus Therapeutics, including CEO Bradley L. Campbell and Chief Human Resources Officer David Michael Clark, reported the sale of the company's common stock. Such insider trading may raise market concerns about the company's future
On December 19th, BioMarin stated that the acquisition will expand its influence in the field of rare metabolic diseases and expects the transaction to immediately increase revenue upon completion, causing BioMarin's stock price to drop about 3% in pre-market trading. There is an increase in merger and acquisition activity in the rare disease sector, attracting market attention.
</li>
</ol>
Vision Marine Tech rose 20.55% in pre-market trading. Based on recent key news:
On December 17th, Vision Marine Technologies announced the pricing details of its public offering. This news drove the stock price up as investors are confident in the company's future growth potential. There is a growing demand in the electric vessel market

Banco Santander SA-Spon pre-market down 4.30%; Prophase Labs pre-market up 88.20%; Aime Medical pre-market up 29.93%; Vision Marine Tech pre-market up 20.55%

Tracking Unusual Activity

Banco Santander SA-Spon

Pre-market hot trades in US stocks: Banco Santander SA-Spon fell 4.3% in pre-market trading, as the establishment of new branches and green bonds failed to boost its stock price